Researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers in adults with HIV, marking the first clinical evidence that the drug may influence human aging beyond its metabolic effects.
Indian drugmaker Dr. Reddy's Laboratories announced it is delaying commercial production of its generic semaglutide (Ozempic) after discovering an unspecified issue with the active pharmaceutical ingredient in some batches. Shares fell as much as 6.5%.
New research reveals that approximately 10% of people carry specific genetic variants that make popular diabetes and weight-loss drugs like Ozempic and Wegovy significantly less effective, providing the first genetic explanation for variable drug response.
